CliffBio
small molecule

LEXAPRO

ESCITALOPRAM OXALATE

Loss of exclusivityMay 2026FDA regulatory exclusivity expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameLEXAPRO
Active ingredientESCITALOPRAM OXALATE
StrengthEQ 20MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2002
Marketing statusRX

Regulatory exclusivity

CodeExpires
NPPMay 2026

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

LEXAPRO patent cliff — loss of exclusivity May 2026 | CliffBio